Epithelial ovarian carcinoma (EOC) is the most lethal gynaecologic malignancy ([@bib25]). Despite advances in surgery and new chemotherapy regimens over the last few decades, the reported 5-year survival rate for patients with EOC ranges from 25 to 30% or even less ([@bib11]; [@bib1]). However, predictions for the patients\' prognosis can be variable and inaccurate. The identification of a new cancer biomarker, in addition to common clinicopathological risk factors to select patients with good or bad outcome, will assist the follow-up management of EOC after surgery. Thus, novel prognostic and predictive markers are necessary to improve the assessment of patient outcome and to guide more targeted and individualised therapeutic decisions.

Tumour necrosis factor-*α*-induced protein 8 (TNFAIP8) family, a new subfamily of death effector domain that contains proteins, consists of TNFAIP8, TIPE1, TIPE2 and TIPE3 ([@bib8]; [@bib27]). Among them, TNFAIP8 (also known as SCC-S2, GG2-1 and MDC-3.13), the first identified and most investigated member, is a 21 kDa cytosolic TNF-*α*-inducible antiapoptotic and oncogenic molecule ([@bib13], [@bib12]). Tumour necrosis factor-*α*-induced protein 8 was originally identified based on the comparison of a primary human head and neck squamous cell carcinoma cell line with its matched metastatic cell line established from the recurrent tumour after radiation therapy ([@bib22]). Tumour necrosis factor-*α*-induced protein 8 was discovered to express in various human cancer cell lines, with higher levels in K562, MOLT4, A549 and SKOV-3 and lower levels in SW480 ([@bib13]). Overexpression of TNFAIP8 in cancer cells is induced by TNF-*α* and by the activation of NF-*κ*B in various cells ([@bib10]; [@bib13]; [@bib29]; [@bib32]), which enhance cell survival and proliferation by reducing apoptosis through the inhibition of the apoptotic protein caspase-8 and caspase-3 activity ([@bib13]; [@bib29]; [@bib32], [@bib30]; [@bib14]). Collectively, the above functional studies suggest that TNFAIP8 may have a crucial role in tumour cell proliferation, migration, invasion and metastasis.

With regard to the possible role of TNFAIP8 in tumorigenesis and its progression, TNFAIP8 overexpression has frequently occurred in several types of cancer tissues and has exhibited clinical relevance ([@bib12]; [@bib5]; [@bib9]; [@bib15]; [@bib18]; [@bib33], [@bib31]; [@bib24]). As of this writing, no studies on TNFAIP8 in primary EOC tissues have been conducted. Therefore, in this study, we evaluated TNFAIP8 expression in EOC and its clinical significances following the guideline for REMARK ([@bib17]). The data showed the crucial role of TNFAIP8 as a prognostic and metastatic marker as well as a novel potential therapeutic target in EOC.

Materials and methods
=====================

Patients and clinical tissue samples
------------------------------------

Archived formalin-fixed, paraffin-embedded specimens used for immunohistochemistry (IHC) were obtained from 202 patients with EOC and 30 patients with normal ovaries who were surgically treated in The Affiliated Tumor Hospital of Harbin Medical University from January 2004 to December 2006. The matching primary lesion, metastatic lymph node, peritoneum and omentum were available for 20 of the primary EOCs. In addition, fresh tissues from 30 patients, including tumour tissues (*n*=20) and normal tissues (*n*=10), were collected and stored at −80 °C immediately after resection to extract protein and RNA. Patients with normal ovaries underwent hysterectomy with oophorectomy for benign uterine disease. All of the patients with EOC underwent primary cytoreduction followed by standard platinum-based combination chemotherapy ([@bib19]). For early-stage patients, adequate surgery staging including para-aortic and pelvic lymph node dissection was indicated. Patients with tumour nodules outside the pelvis equal or less than 2 cm also had pelvic and para-aortic lymph node dissection ([@bib7]). For advanced-stage patients, suspicious and/or enlarged nodes should be ablated if possible. None of the patients received chemotherapy, radiotherapy or immunotherapy before the surgery.

The clinicopathological characteristics of EOCs are described in [Table 1](#tbl1){ref-type="table"}. Median age of the EOC patients was 54, ranging from 25 to 80 (years), and mean age was 54.23±10.513 (years±s.d.). Histological typing was classified according to World Health Organization classification standards ([@bib28]). The grading and staging of tumours were performed according to the International Federation of Gynecologists and Obstetricians (FIGO) staging system ([@bib2]). Optimal cytoreduction was defined according to the Gynecologic Oncology Group. The largest residual tumour nodule measuring 1 cm or less was determined by the operating surgeon ([@bib20]). This study was approved by the Institute Research Medical Ethics Committee of Harbin Medical University. All of the patients gave their informed consent.

Platinum sensitivity was defined as a complete response/partial response (PR) to primary platinum chemotherapy with no evidence of progression at 6 months. Platinum resistance was defined as a complete response/PR to primary platinum chemotherapy with progression within 6 months of completing therapy or with less than a PR to initial chemotherapy. Platinum refractoriness was defined as progressive disease/stable disease on primary platinum chemotherapy.

Follow-up evaluation
--------------------

Examinations performed during the follow-up period included a pelvic MRI, a colour Doppler ultrasound of the liver and kidney, X-rays and serum levels of CA-125 according to the National Comprehensive Cancer Network criteria ([@bib19]). (every 3 months for 2 years; 6-month intervals for the next 3 years; and after 5 years, every 12 months for life). Cancer-specific survival (CSS) was defined as the period from the date of surgery until death or to the time of the most recent follow-up. Patients who died of other disease were excluded. Disease-free survival (DFS) was defined as the period from the date of surgery to recurrence. All EOC patients were followed up until death or the cut-off date of December 30 2012.

RNA preparation and reverse transcription
-----------------------------------------

Total RNA was extracted from fresh frozen samples according to the protocol of RNAsimple Total RNA Kit (DP419, TIANGEN, Beijing, China) after ensuring that tumour contained more than 75% tumour cells and approval by pathologists in the pathology department. RNA quality and concentration were measured using a NanoDrop 2000 spectrophotometer (Thermo, Wilmington, DE, USA). Reverse transcriptional RNA was synthesised from 2.0 *μ*g total RNA in a 14.5 *μ*l reaction mixture using 2 × Power Taq PCR MasterMix kit (PR1702, BioTeke, Beijing, China) following the manufacturer\'s instructions. Total RNA was reverse-transcribed with 1 *μ*l of Super M-MLV Reverse Transcriptase (PR6502, BioTeke) in a reaction container (25 °C for 10 min, 42 °C for 50 min and 95 °C for 5 min).

Real-time quantitative reverse transcriptase--PCR (RT--PCR)
-----------------------------------------------------------

Real-time quantitative RT--PCR was performed using the Exicycler 96 real-time RT--PCR system (A-2060, BIONEER, Daejeon, Korea) and SYBR Green mastermix (SY1020, Solarbio, Beijing, China). The primers to TNFAIP8 were designed as follows: forward, 5′-TGAAGATGGAGCACTGCTGA-3′ reverse, 5′-GGTCTGTTACCCGTTAGGAAG-3′. *β*-Actin was applied as the internal reference, its primers were as follows: forward, 5′-CTTAGTTGCGTTACACCCTTTCTTG-3′ reverse, 5′-CTGTCACCTTCACCGTTCCAGTTT-3′. Amplification was performed under the following conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 10 s, 60 °C for 20 s and 72 °C for 30 s. Experiments were performed in triplicate in the same reaction. The results of the real-time quantitative RT--PCR experiments were calculated using the 2^−ΔΔC(t)^ method ([@bib16]).

Western blot analysis
---------------------

Frozen tissue samples were homogenised in RIPA buffer consisting of 1% protease inhibitor mixture. The mixture was centrifuged at 12 000 g for 15 min at 4 °C and the supernatant was obtained. Total proteins were quantified using the Bradford method (Thermo Scientific, Waltham, MA, USA). Briefly, 30 *μ*g of a protein extract was separated by 12% SDS polyacrylamide gel electrophoresis and transferred onto PVDF film (Millipore Company, Billerica, MA, USA). The membranes were blocked by 2% (bovine serum albumin) BSA at 37 °C for 1 h and incubated overnight at 4 °C. After a standard washing, the film was incubated with horseradish peroxidase-labeled secondary antibody for 1 h at room temperature and washed again. The blots were stained using a SuperSignal kit (Pierce, Rockford, IL, USA) and imaged by a charge-coupled camera LAS4000 (Fujifilm, Tokyo, Japan). A polyclonal rabbit anti-TNFAIP8 (ab64988, Abcam, Cambridge, MA, USA) was used for TNFAIP8 detection (1 : 500 diluted). *β*-Actin, a loading control, was detected using a polyclonal antibody (sc-130301, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The experiment was repeated in triplicate.

Immunohistochemistry
--------------------

Immunohistochemistry staining for TNFAIP8 was performed using the Two-Step IHC Detection Reagent (PV-6001) kit (Zhong Shan Golden Bridge Biological Technology Inc., Beijing, China) according to the manufacturer\'s instructions. Paraffin-embedded tissue blocks of the ovarian specimen were cut in a microtome to the desired thickness (∼4 *μ*m is ideal for IHC) and stained with H&E for tumour confirmation. In brief, tissue sections were deparaffinized in xylene and rehydrated in a series of graded alcohol using standard procedures. The sections were then immersed in 3% hydrogen peroxide for 10 min to remove endogenous peroxidase. Antigen retrieval was performed using a pressure cooker with 10 mmol l^−1^ citrate buffer (pH 6.0) for 3 min to enhance immunoreactivity. The slides were subsequently incubated with a rabbit polyclonal antibody against TNFAIP8 (1 : 100 dilution; ab64988, Abcam) overnight at 4 °C. After washing with phosphate-buffered saline, the rabbit secondary antibody (Zhong Shan Golden Bridge Biological Technology Inc., Beijing, China) was applied and incubated for 20 min at room temperature. Colour was developed using 3,3′-diaminobenzidine tetrahydrochloride (Dako, Hamburg, Germany). The slides were counterstained with Meyer\'s hematoxylin and dehydrated in ethanol. Finally, the slides were mounted and coverslipped with Resina. The negative control slides were stained with rabbit serum instead of primary antibodies. Non-small-cell lung cancer (NSCLC) with a positive expression of TNFAIP8 was considered as the positive control.

All the tissue sections were analysed by two independent pathologists experienced in evaluating IHC, and who were blinded to the clinicopathological data. The cytoplasmic staining results were scored based on the following criteria: (a) percentage of immunoreactive cells: 0 (0%), 1 (0--10%), 2 (11--50%), 3 (51--70%), 4 (⩾71%); and (b) staining intensity: 0 (negative staining), 1 (weak staining), 2 (moderate staining), 3 (intense staining). The final score for TNFAIP8 expression was the sum of the score for the percentage of positive cells and the intensity score that ranged from 0 to 7 ([@bib26]). In the statistical analysis, a final staining score less than 4 was defined as low expression, and a score equal or more than 4 as high expression. Any score discrepancies were reviewed by the original two pathologists and a senior pathologist until a consensus was reached.

Statistical analysis
--------------------

All of the analyses were performed using SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). For continuous variables, student\'s *t*-test was performed. The *χ*^2^ test was used to analyse the differences of categorical variables. Survival curves were plotted by using the Kaplan--Meier method and compared using the log-rank test. The Cox proportional hazard model was used for the multivariate analysis of the independent prognostic factors for CSS and DFS. Univariate and multivariate logistic regressions with covariate adjustment were used to assess the association between TNFAIP8 overexpression and EOC metastasis. Two-sided *P*\<0.05 was considered as statistically significant.

Results
=======

Tumour necrosis factor-*α*-induced protein 8 mRNA and protein expression in ovarian cancer tissues
--------------------------------------------------------------------------------------------------

The analyses of quantitative real-time RT--PCR and western blot were used to further confirm mRNA and protein levels. The mean expression value of TNFAIP8 mRNA in cancer tissues (6.9985±2.876, normalised by *β*-actin gene expression), was significantly higher than the value (1.0090±0.13674) in normal ovarian tissues (*P*\<0.001, Student\'s *t*-test). There was a 6.9-fold difference between tumours and normal tissues ([Figure 1A](#fig1){ref-type="fig"}).

The difference in TNFAIP8 expression between tumours and normal tissues reflected at protein level was investigated using Western blot. TNFAIP8 was detected as a ∼21-kDa band ([Figure 1B](#fig1){ref-type="fig"}). Expression of TNFAIP8 protein was elevated in samples of EOC tissues (*n*=20) compared with that present in samples of normal ovaries (*n*=10) ([Figures 1C](#fig1){ref-type="fig"}, *P*\<0.001, Student\'s *t*-test).

Association between TNFAIP8 expression and clinicopathologic characteristics in EOCs
------------------------------------------------------------------------------------

Overexpressed TNFAIP8 was detected in 116 samples (57.4%), whereas negative or weak TNFAIP8 immunoreactivity was observed in normal ovarian tissues. TNFAIP8 was clearly localised in the cytoplasmic compartment of the tumour cells ([Figure 2A](#fig2){ref-type="fig"}). Geographic differences were also observed in TNFAIP8 cytoplasmic staining ([Figure 2B](#fig2){ref-type="fig"}), which was more intense in the invasive foci than in the in primary foci among the same patients (20 patients). TNFAIP8 overexpression in ascites was also observed ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

As shown in [Table 1](#tbl1){ref-type="table"}, elevated TNFAIP8 expression was significantly associated with high histologic grade (*P*=0.037), large residual tumour size (*P*=0.014), recurrence (*P*=0.024), response to chemotherapy (*P*\<0.001) and the presence of intraperitoneal metastasis (*P*=0.011) and lymph node metastasis (*P*=0.008). However, no strong association was observed between TNFAIP8 and age, FIGO stage, histological type, ascites and serum CA-125 level (*P*\>0.05). The associations between the mean scores of TNFAIP8 and clinicopathological variables are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Predictive significance of TNFAIP8 expression in EOCs with peritoneum and lymph node metastases
-----------------------------------------------------------------------------------------------

We conducted separate univariate analyses of clinicopathologic variables for the metastasis of the peritoneum and lymph nodes. Following clinical advice, the FIGO stage was excluded in this study. The presence of intraperitoneal metastasis was positively associated with the presence of ascites (*P*=0.009) and large residual tumour size (*P*=0.047). Moreover, a direct correlation between the metastasis of lymph node and high histologic grade (*P*=0.043) and serum CA-125 level (*P*=0.030) was established.

A multivariate logistic regression analysis was performed to evaluate the independently predictive significance of TNFAIP8 overexpression for intraperitoneal metastasis ([Table 2](#tbl2){ref-type="table"}). The result showed that the presence of ascites (*P*=0.003, odds ratio (OR): 2.833, 95% confidence interval (CI): 1.427--5.624) and TNFAIP8 overexpression (*P*=0.014, OR: 2.209, 95% CI: 1.174--4.156) were independently associated with intraperitoneal metastasis. As described above, the multivariate logistic regression analysis demonstrated that TNFAIP8 overexpression was significantly associated with the presence of lymph node metastasis (*P*=0.006, OR: 4.129, 95% CI: 1.491--11.435) ([Table 2](#tbl2){ref-type="table"}).

Prognostic significance of TNFAIP8 expression in EOC patients
-------------------------------------------------------------

Univariate and multivariate analyses were conducted to determine the predictors for CSS and DFS ([Table 3](#tbl3){ref-type="table"}). In the univariate analysis, results revealed that advanced FIGO stage, high histologic grade, large residual tumour size and TNFAIP8 overexpression were significant indicators of poor survival. However, age, histological type, ascites and serum CA-125 level did not affect CSS and DFS (*P*\>0.05). For CSS prediction, advanced FIGO stage (*P*\<0.001, hazard ratio (HR)=6.783, 95% CI: 2.496--18.434), large residual tumour size (*P*=0.001, HR=1.995, 95% CI: 1.240--2.972), and TNFAIP8 overexpression (*P*\<0.001, HR=1.852, 95% CI: 1.322--2.594) were independent factors confirmed by multivariate analysis. The multivariate analysis also showed that advanced FIGO stage (*P*\<0.001, HR=7.213, 95% CI: 2.652--19.618), high histologic grade (*P*=0.027, HR=1.446, 95% CI: 1.043--2.005), large residual tumour size (*P*=0.004, HR=1.777, 95% CI: 1.197--2.637) and TNFAIP8 overexpression (*P*=0.001, HR=1.724, 95% CI: 1.235--2.407) were also independent predictors for DFS.

The 5-year CSS and DFS rates were 22.7% and 16.6%, respectively, in patients with a high level of TNFAIP8 expression, compared with the 51.2 (*P*\<0.001) and 40.1% (*P*\<0.001) in their counterparts. To eliminate the effect of FIGO stage on prognosis, we performed a stage-stratified analysis of all patients according to the level of TNFAIP8 expression and found that TNFAIP8 overexpression highly affected CSS and DFS in patients with advanced FIGO stage (III--IV) (*P*\<0.001 for both). The survival curves for the EOC patients in the two groups stratified by FIGO stage are illustrated in [Figure 3](#fig3){ref-type="fig"}.

Discussion
==========

To the best of our knowledge, the present study is the first to argue that unlike in normal ovarian tissues, TNFAIP8 expression is upregulated at both mRNA and protein levels in EOCs. High expression level of TNFAIP8 and its cytoplasmic localisation are significantly associated with high histologic grade, large residual tumour size, recurrence, response to chemotherapy, and, most importantly, the presence of intraperitoneal and lymph node metastases. The preferential expression of TNFAIP8 in EOCs also serves as an independent prognostic factor for poor CSS and DFS, particularly in advanced EOCs (FIGO stage III--IV).

The increasing incidence, delayed detection and poor prognosis of this disease underline the need to search for new strategies for diagnosis, follow-up and treatment. In line with the possible role of TNFAIP8 in human tumorigenesis, previous studies have proven that TNFAIP8 overexpression was detected in several human malignant tumours at both mRNA and protein levels ([@bib12]; [@bib5]; [@bib9]; [@bib15]; [@bib18]). Positive correlations of TNFAIP8 with histologic grade, residual tumour size, recurrence and metastases of the peritoneum and lymph node have been demonstrated in the current study. The elevated TNFAIP8 expression that correlates with tumour stage and lymph node metastasis was observed in pancreatic cancer, colon cancer, NSCLC and oesophageal squamous cell cancer ([@bib5]; [@bib9]; [@bib15]; [@bib18]). In NSCLC and oesophageal squamous cell cancer, TNFAIP8 was proven to be a poor prognostic marker, although it was not an independent factor ([@bib5]; [@bib9]). [@bib31] argued that nuclear TNFAIP8 overexpression is an independent predictor of recurrent prostate cancer. Furthermore, functional variants in TNFAIP8 were believed to result in tumour progression and poor outcome of cervical cancer by inhibiting the response of tumour cells to platinum drugs, particularly cisplatin and nedaplatin ([@bib24]). [@bib33] also observed that the polymorphism of TNFAIP8 was correlated with non-Hodgkin\'s lymphoma. Collectively, these data suggest that TNFAIP8 has a significant role in the oncogenesis and progression of human malignancies. Though no association between FIGO stage and TNFAIP8 expression (low and high) was observed in this study, we found that the mean scores of TNFAIP8 correlated with FIGO stage. Therefore, further confirming this conclusion in patients with EOC is of paramount importance.

Clinically, the presence of EOC metastasis is not always easy to assess in daily practice, which effectively affects the survival outcome ([@bib6]; [@bib4], [@bib3]). The elucidation of molecules and signalling pathways that drive metastasis in EOC is likely to provide new avenues for the early identification and therapeutic intervention of aggressive EOC. A multivariate logistic regression analysis was proposed to further characterise this clinical implication of TNFAIP8 in EOCs. Interestingly, we clarified that TNFAIP8 may be useful as an adjunct in the evaluation of metastases of the peritoneum and lymph node. The fact that TNFAIP8 is highly expressed in the invasive foci and the areas of primary lesion ([Figure 2B](#fig2){ref-type="fig"}) reflects its preferential expression in areas of intense tumour growth. In preliminary functional studies, overexpression of exogenous TNFAIP8 or inhibition of TNFAIP8 with antisense oligo could modify the metastatic properties in MDA-MB 435 cells ([@bib12]). In addition, the depletion of TNFAIP8 expression using siRNA could simultaneously decrease the expression of fundamental elements of the extracellular matrix and VEGFR-2 in PC-3 cells ([@bib31]). Conversely, in lung cancer cells, downregulation of TNFAIP8 was believed to result in a significant inhibition of cancer cell growth and invasion, which was independent of MMPs ([@bib5]). Taken together, a dramatic breakthrough has come with the identification of the aggressive and invasive effects of TNFAIP8 in tumours.

Thus far, evidence linking TNFAIP8 oncogene to the survival of several cancer types ([@bib5]; [@bib9]; [@bib24]) without controlling the tumour stage exists. Indeed, FIGO stage in EOCs is pivotal for survival ([@bib21]) with that the 5-year survival rate of early-stage EOC varies from 50 to 85% ([@bib23]). By performing a stage-stratified analysis, we demonstrated that TNFAIP8 overexpression may be a prognostic indicator for advanced EOC.

In the light of the above findings, TNFAIP8 can, therefore, be considered as a novel marker of intraperitoneal and lymph node metastases and a promising therapeutic target in EOC patients. Although the results are intriguing, this investigation has limitations. The current study is a retrospective analysis with a limited number of patients. Thus, a more thorough investigation in a larger series of patients is necessary to confirm the use of this new variable. The exploration of possible mechanism of EOC metastasis caused by TNFAIP8 overexpression is ongoing in our laboratory.
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![**Tumour necrosis factor-*α*-induced protein 8 elevated expression in clinical EOC tissues.** (**A**) Real-time PCR assay of TNFAIP8. Histogram of TNFAIP8 mRNA expression in normal ovaries (N, *n*=10) and in EOC tissues (T, *n*=20). The levels of *β*-actin were used as an internal control, and the TNFAIP8 mRNA expression was calculated by 2^−ΔΔCt^ method. The relative TNFAIP8 mRNA expression was elevated in EOCs compared with normal ovaries. The data are presented as mean±s.d., \**P*\<0.05. Normalisation: TNFAIP8/actin was first calculated and then normal pooled and normalised to 1.00. (**B**) Representative western blot analysis of TNFAIP8 expression in ovarian tissues. Protein samples obtained from normal ovaries (N, *n*=10) and EOCs (T, *n*=20) were analysed using SDS--PAGE followed by immunoblotting with antibody against TNFAIP8. The levels of *β*-actin were used as an internal control. (**C**) Histogram of pooled data from normal ovaries (N, *n*=10) and EOCs (T, *n*=20). The expression of TNFAIP8 protein was significantly increased in EOCs compared with normal ovaries. The data are presented as mean±s.d., \**P*\<0.05. Normalisation: TNFAIP8/actin was first calculated and then normal pooled and normalised to 1.00.](bjc2013501f1){#fig1}

![**Representative photomicrographs of TNFAIP8 immunohistochemical staining.** (**A**) Tumour necrosis factor-*α*-induced protein 8 expression in ovarian tissues. (a) Positive control in lung cancer. (b) Negative staining in normal ovary. (c) High expression in serous histotypes. (d) Low expression in serous histotypes. (e) High expression in mucinous histotypes. (f) Low expression in mucinous histotypes. (g) High expression in endometrioid histotypes. (h) Low expression in endometrioid histotypes. (i) High expression in clear cell histotypes. (j) Low expression in clear cell histotypes ( × 400 original magnification). (**B**) TNFAIP8 expression in primary and metastatic lesions from the same patient. (a) Primary lesion. (b) Metastatic omentum. (c) Metastatic peritoneum. (d) Metastatic lymph node ( × 400 original magnification).](bjc2013501f2){#fig2}

![**A stage-stratified analysis of TNFAIP8 expression in patients with EOC.** Survival curves showing the correlation of TNFAIP8 with CSS and DFS in EOC patients in different FIGO stages. (**A**) Cancer-specific survival in FIGO stage I. (**B**) Disease-free survival in FIGO stage I. (**C**) Cancer-specific survival in FIGO stage II. (**D**) Disease-free survival in FIGO stage II. (**E**) Cancer-specific survival in FIGO stage III--IV. (**F**) Disease-free survival in FIGO stage III--IV.](bjc2013501f3){#fig3}

###### Association between TNFAIP8 expression levels and clinicopathological characteristics of EOC

                                           **TNFAIP8 expression**               
  ---------------------------------- ----- ------------------------ ----------- ----------
  **Age (years)**                                                               
  ⩽54                                 97   45 (46.4)                52 (53.6)     0.292
  \>54                                105  41 (39.1)                64 (60.9)        
  **FIGO stage**                                                                
  I                                   15   9 (60.0)                 6 (40.0)      0.068
  II                                  26   15 (57.7)                11 (42.3)        
  III--IV                             161  62 (38.5)                99 (61.5)        
  **Histologic grade**                                                          
  G1/G2                               76   42 (55.3)                34 (44.7)     0.005
  G3                                  126  44 (34.9)                82 (65.1)        
  **Histological type**                                                         
  Serous                              128  55 (43.0)                73 (57.0)     0.138
  Mucinous                            29   9 (31.0)                 20 (69.0)        
  Endometrioid                        33   19 (57.6)                14 (42.4)        
  Clear cell                          12   3 (25.0)                 9 (75.0)         
  **Residual tumour size**                                                      
  ⩽1 cm                               168  78 (46.4)                90 (53.6)     0.014
  \>1 cm                              34   8 (23.6)                 26 (76.4)        
  **Ascites**                                                                   
  ⩽100 ml                             54   20 (37.0)                34 (63.0)     0.336
  \>100 ml                            148  66 (44.6)                82 (55.4)        
  **Serum CA-125 level**                                                        
  ⩽35 U ml^−1^                        65   25 (38.5)                40 (61.5)     0.415
  \>35 U ml^−1^                       137  61 (44.5)                76 (55.5)        
  **Recurrence**                                                                
  Yes                                 95   33 (34.7)                62 (65.3)     0.024
  No                                  107  53 (49.5)                54 (50.5)        
  **Response to chemotherapy**                                                  
  Platinum sensitive                  134  73 (54.5)                61 (45.5)    \< 0.001
  Platinum resistant                  46   10 (21.7)                36 (78.3)        
  Platinum refractory                 22   3 (13.6)                 19 (86.4)        
  **Intraperitoneal metastasis**                                                
  Yes                                 137  50 (36.5)                87 (63.5)     0.011
  No                                  65   36 (55.4)                29 (44.6)        
  **Lymph node metastasis no.=81**                                              
  Yes                                 47   15 (31.9)                32 (68.1)     0.008
  No                                  34   21 (63.6)                13 (36.4)        

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; TNFAIP8=tumour necrosis factor-*α*-induced protein 8; no.=number of patients; %=percentage of patients.

Note: 81 patients underwent para-aortic and pelvic lymph node dissection.

###### The relationships of TNFAIP8 expression with intraperitoneal and lymph node metastasis by ultivaritae analysis

  **Variable**                                **B**    **S.E.**   ***P*-value**   **OR**    **95% CI**
  ------------------------------------------ -------- ---------- --------------- -------- ---------------
  **Intraperitoneal metastasis (no.=202)**                                                
  **Residual tumour size**                                                                
  ⩽1 cm *vs* \>1 cm                           0.929     0.500         0.063       2.533    0.950--6.753
  **Ascites**                                                                             
  ⩽100 ml *vs* \>100 ml                       1.041     0.350         0.003       2.833    1.427--5.624
  **TNFAIP8 expression**                                                                  
  Low *vs* high                               0.792     0.323         0.014       2.209    1.174--4.156
  **Age (years)**                                                                         
  ⩽54 *vs* \>54                               −0.172    0.318         0.588       0.842    0.451--1.570
  **Lymph node metastasis (no.=81)**                                                      
  **Histologic grade**                                                                    
  G1/G2 *vs* G3                               0.923     0.510         0.070       2.518    0.926--6.845
  **Serum CA-125 level**                                                                  
  ⩽35 U ml^−1^ *vs* \>35 U ml^−1^             1.079     0.558         0.053       2.943    0.986--8.787
  **TNFAIP8 expression**                                                                  
  Low *vs* high                               1.418     0.520         0.006       4.129    1.491--11.435
  **Age (years)**                                                                         
  ⩽54 *vs* \>54                               0.061     0.508         0.905       1.062    0.392--2.878

Abbreviations: B and S.E.=the parameter estimator of association coefficient and its standard error; CI=confidence interval; OR=odds ratio; TNFAIP8=tumour necrosis factor-*α*-induced protein 8; no.=number of patients.

###### Univariate and multivariate analysis for cancer-specific survival and disease-free urvivlal.

                              **Cancer-specific survival**   **Disease-free survival**                                                
  -------------------------- ------------------------------ --------------------------- ---------- ---------- ----------------------- ----------
  **Age (years)**                                                                                                                     
  ⩽54                                                                                                                                      
  \>54                                   0.063                          ---                ---       0.218              ---              ---
  **FIGO stage**                                                                                                                      
  I                                                                    1.000             \< 0.001                      1.000           \< 0.001
  II                                                           2.518 (0.819--7.743)       0.107                2.659 (0.865--8.175)     0.088
  III--IV                               \< 0.001               6.783 (2.496--18.434)     \< 0.001   \< 0.001   7.213 (2.652--19.618)   \< 0.001
  **Histologic grade**                                                                                                                
  G1/G2                                                                1.000                                           1.000               
  G3                                     0.040                 1.362 (0.980--1.892)       0.066      0.040     1.446 (1.043--2.005)     0.027
  **Histological type**                                                                                                               
  Serous                                                                                                                                   
  Mucinous                                                                                                                                 
  Endometrioid                                                                                                                             
  Clear cell                             0.082                          ---                ---       0.052              ---              ---
  **Residual tumour size**                                                                                                            
  ⩽1 cm                                                                1.000                                           1.000               
  \>1 cm                                \< 0.001               1.995 (1.340--2.972)       0.001     \< 0.001   1.777 (1.197--2.637)     0.004
  **Ascites**                                                                                                                         
  ⩽100 ml                                                                                                                                  
  \>100 ml                               0.464                          ---                ---       0.799              ---              ---
  **Serum CA-125 level**                                                                                                              
  ⩽35 U ml^−1^                                                                                                                             
  \>35 U ml^−1^                          0.216                          ---                ---       0.189              ---              ---
  **TNFAIP8 expression**                                                                                                              
  Low                                                                  1.000                                           1.000               
  High                                  \< 0.001               1.852 (1.322--2.594)      \< 0.001   \< 0.001   1.724 (1.235--2.407)     0.001

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HR=hazard ratio; CI=confidence interval; TNFAIP8=tumour necrosis factor-*α*-induced protein 8.
